6/10/2015 | DD | Dendreon emerges from bankruptcy; liquidation plan effective June 10
|
6/2/2015 | DD | Dendreon wins confirmation of Chapter 11 plan of liquidation
|
5/21/2015 | DD | Dendreon reports $2.09 million of income from operations for April
|
5/1/2015 | DD | Dendreon stockholder group denied official committee representation
|
4/21/2015 | DD | Dendreon operating loss shrinks to $316,000 in March; revenue falls
|
4/15/2015 | DD | Dendreon disclosure statement approved; plan hearing set for June 2
|
4/10/2015 | DD | Dendreon wins 110-day exclusivity extension to continue plan talks
|
4/8/2015 | DD | Dendreon: SEC won’t take enforcement action following investigation
|
3/20/2015 | DD | Dendreon loses $22.9 million from operations in February; revenue down
|
3/12/2015 | DD | Dendreon U.S. trustee eliminates one member of creditor committee
|
3/10/2015 | DD | Dendreon liquidation plan will distribute $495 million from asset sale
|
3/9/2015 | HY | Market Commentary: Crestwood, Masonite, HealthSouth drive by; calendar builds massively; Whiting jumps on sale talk
|
3/6/2015 | DD | Dendreon eyes 110-day extension of exclusive periods to negotiate plan
|
2/23/2015 | DD | Dendreon $495 million asset sale closes Feb. 23; two directors resign
|
2/20/2015 | DD | Dendreon’s $495 million sale of all assets to Valeant backed by court
|
2/19/2015 | DD | Dendreon total sale price increased to $495 million under amendment
|
2/17/2015 | DD | Dendreon sees loss of $5 million on $21 million of revenue in January
|
2/10/2015 | DD | Dendreon to seek approval of $400 million Valeant bid; auction off
|
2/5/2015 | DD | Dendreon stalking horse bidder OK’d, increases bid to $400 million
|
2/5/2015 | DD | Dendreon $296 million stalking horse bid OK’d; sale hearing Feb. 20
|
1/29/2015 | DD | Dendreon gets stalking horse bid from Valeant, extends bid deadline
|
1/29/2015 | DD | Dendreon court allows creditor committee to employ joint legal counsel
|
1/27/2015 | DD | Dendreon bid deadline pushed back two days to continue bidder talks
|
1/26/2015 | DD | Dendreon committee wins approval to hire Deloitte as financial adviser
|
1/21/2015 | DD | Dendreon posts $4.59 million December loss from operations; revenue up
|
12/31/2014 | CV | Outlook 2015: Cheaper pricing, strong issuance eyed after convertibles pull back from 2014 levels
|
12/30/2014 | DD | Dendreon continuing asset sale process without picking stalking horse
|
12/24/2014 | DD | Dendreon marks $9.96 million from operations during November period
|
12/23/2014 | DD | Dendreon committee eyes employment of joint counsel, financial adviser
|
12/17/2014 | DD | Dendreon wins support of asset sale procedures, stalking horse terms
|
12/9/2014 | DD | Dendreon court gives final approval on procedures for equity trading
|
12/3/2014 | DD | Dendreon landlord of leased warehouse objects to prosed sale timeline
|
11/19/2014 | DD | Dendreon U.S. trustee appoints unsecured creditor committee
|
11/14/2014 | BKCVDDEMHY | Prospect News reports four new defaults for week of Nov. 6 to Nov. 12
|
11/13/2014 | DD | Dendreon granted interim court approval of equity trading procedures
|
11/12/2014 | PP | Market Commentary: New Isis Pharmaceuticals trades below par, slips on hedge; Dendreon steady; Home Inns adds
|
11/12/2014 | CV | Market Commentary: New Isis Pharmaceuticals trades below par, slips on hedge; Dendreon steady; Home Inns adds
|
11/12/2014 | CV | Market Commentary: Morning Commentary: New Isis trades below par, slips on hedge; Dendreon trading at 55.5
|
11/10/2014 | CVDD | Dendreon files for Chapter 11, convertibles to be exchanged for stock
|
11/10/2014 | PP | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Morning Commentary: Dendreon drops after bankruptcy filing; Salix Pharmaceuticals bounces slightly
|
11/10/2014 | CVDD | Dendreon files for Chapter 11, convertibles to be exchanged for stock
|
8/13/2014 | CVDD | Dendreon doubts ability to repay 2.875% convertibles, explores options
|
8/12/2014 | CV | Market Commentary: New Aegerion flat to better amid weak shares; Nuance bonds active after earnings, call
|
5/8/2014 | CV | Market Commentary: Cobalt gains on debut; existing Cobalt slips; Molycorp slides after earnings; Insulet adds
|
1/14/2014 | CV | Market Commentary: Midday Commentary: Hutchinson higher after preliminary earnings; Dendreon moves up to 70
|
1/14/2014 | CV | Market Commentary: Hutchinson, Dendreon higher after preliminary earnings; Goodrich looks rich; Intel active
|
1/14/2014 | DD | Market Commentary: NII trades, though at lower volume; Thompson Creek up on stock upgrade; Dendreon converts firm
|
10/28/2013 | CV | Market Commentary: Midday Commentary: NQ Mobile in focus after fraud allegations; Qihoo, Ctrip.com under pressure
|
10/28/2013 | CV | Market Commentary: NQ Mobile rises on parity basis as shares slide again; Qihoo, Ctrip.com down on hedge
|
9/27/2013 | CV | Market Commentary: Midday Commentary: Alpha Natural flat after Goldman upgrade; Dendreon eyed on positive drug data
|
9/27/2013 | CV | Market Commentary: Tower Group tumbles; UAL preferreds outperform shares; Alpha Natural flat after upgrade
|
8/30/2013 | CV | Market Commentary: AMR gains altitude as judge sets November anti-trust court date; Dendreon notes higher
|
8/23/2013 | DD | Market Commentary: AMR quiet but ends week higher, touts plan; Penney firms, Nokia busy; Dendreon converts ease
|
8/16/2013 | CV | Market Commentary: New JDS Uniphase jumps after pricing on rich end; Merrimack extends slide; AMR wanes
|
8/13/2013 | CV | Market Commentary: AMR stumbles after Justice moves to block merger; new Rambus edges up outright, on swap
|
8/12/2013 | CV | Market Commentary: Tesla down outright, better dollar neutral; Dendreon weakens; Web.com adds; Rambus on tap
|
8/9/2013 | CV | Market Commentary: Web.com prices deal; YRC falls as Credit Suisse hired; Dendreon declines; MolyCorp drops
|
8/5/2013 | CV | Market Commentary: MOVE launches convertible offering; trader says primary primed for surge in new issues
|
6/21/2013 | CV | Market Commentary: Convertibles heavier as fear dominates tone; bank preferreds down; IG paper lower in line
|
5/10/2013 | CV | Market Commentary: Theravance mixed on COPD drug approval; Meritor improves; Electronic Arts extends gains
|
5/9/2013 | CV | Market Commentary: Electronic Arts convertibles gain on hedge; CACI, WebMD bid higher; Dendreon disappoints
|
3/22/2013 | CV | Market Commentary: Convertibles quiet; Walter improves on hedge; MGIC slips on hedge; Dendreon wavers
|
2/20/2013 | CV | Market Commentary: Dendreon, Goodrich pull back; Forestar sells $110 million bonds; Post looks slightly cheap
|
1/14/2013 | CV | Market Commentary: Dendreon adds outright; InterMune intends to price notes, shares; Lennar earnings on tap
|
12/11/2012 | CV | Market Commentary: WebMD active, unchanged as shares surge; AMR firms; Cobalt to price $1.2 billion offering
|
12/10/2012 | CV | Market Commentary: Bottomline extends gains; Dendreon adds about a point; A123 surges on auction; Molycorp up
|
11/5/2012 | CV | Market Commentary: BioMarin up on drug data; Walter Investment pulls back; convertibles pause for elections
|
11/2/2012 | CV | Market Commentary: Dendreon higher after wider loss; Vertex up on hedge after earnings miss; Chesapeake quiet
|
10/29/2012 | CV | Market Commentary: Convertibles silent: U.S. equity, bond markets shut as Sandy approaches; data delays eyed
|
7/31/2012 | CV | Market Commentary: Dendreon drops back into 60s on restructuring; ADM flat; Standard Pacific offering on tap
|
7/30/2012 | CV | Market Commentary: Convertibles mostly quiet; Kodak gains ahead of auction; Navistar firms; SanDisk mixed
|
7/24/2012 | CV | Market Commentary: WebMD down on warning; Dendreon better on takeout rumor; Virgin Media tighter after earnings
|
7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
6/13/2012 | CV | Market Commentary: New United Technologies units trade at 51; USEC up on DOE cost-sharing deal; Dendreon flat
|
6/5/2012 | CV | Market Commentary: Central European drops on restatement news; Illumina comes in slightly; Medicines Co. on tap
|
6/4/2012 | CV | Market Commentary: Convertibles see broad-based action; Dendreon down after rival's drug news; Salesforce steady
|
6/4/2012 | DD | Market Commentary: Bon-Ton bounces on exchange offer; Chesapeake churns on board shakeup; Dendreon declines
|
5/17/2012 | CV | Market Commentary: Dendreon declines after J&J drug news; Patriot Coal keeps sliding; Chesapeake lower again
|
5/9/2012 | CV | Market Commentary: Reoffered Annaly steady; Chiquita down after earnings; Human Genome unfazed by hostile bid
|
5/8/2012 | CV | Market Commentary: Thompson Creek slides; Annaly on tap; Dendreon drops outright, on hedge; Salix seen flat
|
3/27/2012 | CV | Market Commentary: Lennar flat to slightly higher on hedge on earnings; Radian steady; Dendreon catches a bid
|
3/19/2012 | CV | Market Commentary: Vornado finds buyers, trades with premium; BPZ adds; United States Steel gains 0.25 point on hedge
|
3/8/2012 | CV | Market Commentary: Navistar weaker on hedge after outlook cut; Dendreon drops 2 points on positive J&J drug study
|
2/27/2012 | CV | Market Commentary: Dendreon drops on outlook; Cheniere gains on Blackstone investment; DealerTrack to price
|
2/7/2012 | CV | Market Commentary: Coinstar jumps after earnings, Verizon deal; Dendreon edges slightly higher after pop
|
1/25/2012 | CV | Market Commentary: Illumina 'rips' higher outright, expands on hedge; Life, Human Genome move in sympathy
|
1/9/2012 | CV | Market Commentary: Convertibles revert to 'quiet'; Alcoa firm to better ahead of earnings; Amgen steady
|
1/6/2012 | CV | Market Commentary: Convertibles start year strong; Regeneron jumps to 104; Dendreon gains; RF Micro drops
|
1/5/2012 | CV | Market Commentary: Dendreon jumps on better Provenge sales; three Equinix convertibles add; Kodak lower
|
12/30/2011 | CV | Outlook 2012: Convertibles poised for modest gains after 2011's mostly negative returns
|
12/6/2011 | CV | Market Commentary: Dendreon adds on sale of royalty interest; Gilead trades on debt offering; Clearwire jumps
|
11/3/2011 | CV | Market Commentary: Jefferies extends losses; New Human Genome paper flat dollar neutral; MGM adds premium
|
9/28/2011 | CV | Market Commentary: Stillwater still falling after debt sale delayed; Horizon Lines extends exchange deadline
|
9/13/2011 | CV | Market Commentary: InterMune looks rich on revised terms; US Airways' premium comes in a point; Best Buy dips
|
9/9/2011 | CV | Market Commentary: Convertibles under pressure as equities drop; Amerigroup, RadioShack lower; Dendreon flat
|
8/9/2011 | CV | Market Commentary: Convertibles whip around; Hercules Offshore adds; Dendreon eases dollar neutral, MGM flat
|
8/5/2011 | CV | Market Commentary: Convertibles see limited bargain hunting; Vertex up on short covering; high grade firms
|
8/4/2011 | CV | Market Commentary: Convertibles plummet; PMI flickering out; Central European Distribution paper moves lower
|
5/3/2011 | CV | Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
|
4/21/2011 | CV | Market Commentary: Gilead, United Continental slip; Dendreon, WebMD, GM islands of activity in quiet session
|
4/14/2011 | CV | Market Commentary: Dendreon slips a point on hedge; Medtronic Bs add as As hit maturity; Sunrise deal on tap
|
4/4/2011 | CV | Market Commentary: Horizon Lines takes another leg down; Life Technologies slips; Dendreon up; Meritor steady
|
3/31/2011 | CV | Market Commentary: Greenbrier expands on debut; Ramco-Gershenson to price; Dendreon in line on drug news
|
3/11/2011 | CV | Market Commentary: Convertibles market eyes new paper; week sees more than $2 billion of issuance; Cemex off
|
2/3/2011 | CV | Dendreon greenshoe lifts 2.875% convertibles due 2016 to $620 million
|
1/18/2011 | CV | Market Commentary: Dendreon firm on stock outlook; Kinross maintains guidance; Symantec upgraded; Ares plans deal
|
1/14/2011 | CV | New Issue: Dendreon prices upsized $540 million five-year convertible notes at 2.875%, up 40%
|
1/14/2011 | CV | Market Commentary: Dendreon gains with stock after aggressive pricing; Intel results lift techs; Nielsen ahead
|
1/13/2011 | CV | Dendreon to price $500 million five-year convertibles to yield 2.375%-2.875%, up 40%-45%
|
1/13/2011 | CV | Market Commentary: Dendreon to price $500 million convertibles; Allergan active amid possible short covering
|
12/23/2010 | CVLM | Dendreon to exchange shares for $24.85 million of 4.75% convertibles
|
8/24/2010 | SP | New Issue: JPMorgan prices $899,000 28% reverse convertibles linked to Dendreon
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
5/5/2009 | CV | Dendreon to issue shares in exchange for $21.22 million of its 4.75% convertibles due 2014
|
4/28/2009 | CV | Market Commentary: U.S. Steel, SunPower price; financials ease amid stress test chatter; Smithfield trades off
|
8/25/2008 | SP | New Issue: ABN Amro prices $0.5 million 31.75% reverse convertibles linked to Dendreon
|
6/11/2008 | CVHY | Dendreon files $300 million shelf registration
|
4/3/2008 | PP | New Issue: Dendreon to sell $47.36 million of shares, warrants in direct offering
|
4/3/2008 | PP | Market Commentary: Dendreon draws accolades for $47.36 million placement; WSR, Gastem each raise C$8 million from units
|
2/20/2008 | SP | New Issue: ABN Amro prices $0.6 million 27% reverse convertibles linked to Dendreon
|
12/13/2007 | CV | Market Commentary: Convertibles see light volume amid quiet session; A&P leads corporates issuing paper
|
10/12/2007 | PP | New Issue: Dendreon secures $130 million stock purchase agreement
|
6/6/2007 | CV | New Issue: Dendreon prices $75 million seven-year convertibles cheaper than talk at 4.75%, up 17.5%
|
6/6/2007 | CV | Market Commentary: Integra leads new deals with debut gain; Ciena gains dollar-neutral; Dendreon, Cogent set cheaper than talk
|
6/5/2007 | CV | Market Commentary: Amylin gains on debut; Integra higher, Ciena, Dendreon quiet in gray; Cogent, Panda launch unusual deals
|
6/4/2007 | CV | Dendreon talks $75 million seven-year convertibles at 3.5%-4%, up 20%-25%, to price Tuesday
|
6/4/2007 | CV | Market Commentary: Solectron surges on buyout; Amylin flat in gray; Dendreon faces borrow problem; Integra, Ciena plan deals
|
5/18/2007 | SP | New Issue: JPMorgan prices $1 million 20% reverse exchangeables linked to Dendreon
|
5/17/2007 | SP | Market Commentary: JPMorgan sells 25% reverse convertibles linked to Dendreon; Lehman to price to FX notes
|
5/17/2007 | SP | New Issue: JPMorgan prices $1.535 million 25% reverse exchangeables linked to Dendreon
|
5/10/2007 | SP | JPMorgan to price 12.5% reverse exchangeables linked to Dendreon
|
3/19/2007 | CV | Dendreon files $200 million shelf registration
|
11/17/2006 | PP | Market Commentary: BJ's secures $61.5 million from stock sale; Vivus negotiates $33.6 million direct placement of stock
|
11/16/2006 | BT | Market Commentary: Elan bonds on tap; Acorda rises on acquisition buzz; Neurochem, CollaGenex, Dendreon sell PIPEs
|
11/16/2006 | PP | Market Commentary: CollaGenex secures $45.5 million from stock sale; Dendreon prices $45 million offering
|
11/16/2006 | BTPP | New Issue: Dendreon prices $45 million direct placement of stock
|
11/9/2006 | BT | JMP reiterates Dendreon at strong buy
|
11/8/2006 | BT | Dendreon third-quarter revenue up slightly at $84,000
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/25/2006 | BT | Market Commentary: Acorda skyrockets on trial data; GPC, Pharmion, Spectrum rise; Dendreon steady on rivals' news
|
8/24/2006 | BT | Dendreon submits rolling BLA for Provenge to treat advanced prostate cancer
|
8/24/2006 | BT | Market Commentary: Biovail sues U.S. FDA; Dendreon's stock climbs after seeking application from FDA
|
8/14/2006 | BT | Market Commentary: CV Therapeutics falls 10%; Dendreon rises; Biomira up; Neurochem higher by 23.5%
|
8/8/2006 | BT | JMP keeps Dendreon at strong buy
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/5/2006 | BT | Dendreon upgraded to strong buy by JMP
|
6/29/2006 | BT | Dendreon says phase 3 trial shows benefits of Provenge for advanced prostate cancer
|
6/7/2006 | BT | Dendreon publishes study results of Provenge plus Avastin in prostate cancer
|
5/15/2006 | BT | Dendreon says antigen-delivery technology with CA9 prolongs survival up to 40%
|
5/12/2006 | BT | Dendreon reiterated at market outperform by JMP
|
5/10/2006 | BT | JMP reiterates Anadys at strong buy
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/14/2006 | BT | JMP reiterates Dendreon at market outperform
|
2/3/2006 | BT | GE Capital to loan Dendreon an additional $13 million for improvements
|
1/23/2006 | BT | Dendreon kept at market outperform by Jefferies
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/5/2006 | BT | Dendreon secures $7.6 million to build out factory
|
12/12/2005 | BT | Dendreon greenshoe exercised, raising follow-on sale to 11.5 million shares
|
12/8/2005 | BT | JMP reiterates Dendreon at market outperform
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
12/7/2005 | BT | New Issue: Dendreon raises $45 million in follow-on at $4.50, discounted from $5.38 close
|
11/29/2005 | BT | Dendreon amends design of Provenge trial for prostate cancer
|
11/29/2005 | BT | Market Commentary: InterMune, Valeant slip; Voyager IPO chatted up; Encysive higher; Dendreon, ViroPharma decline
|
11/28/2005 | BT | Dendreon to sell 10 million shares on follow-on offering
|
11/7/2005 | BT | JMP maintains Dendreon at market outperform
|
11/7/2005 | BT | Dendreon's Provenge wins fast track designation from FDA
|
10/31/2005 | BT | JMP reiterates Dendreon at market outperform
|
9/15/2005 | BT | Dendreon reiterated by JMP at market outperform
|
8/15/2005 | BT | Dendreon files $150 million stock shelf
|
8/15/2005 | BT | Market Commentary: Cita defers IPO plans for merger talks; Kosan dives on trial delays; Incyte, Abgenix buyers emerge
|
7/22/2005 | BT | Dendreon kept by JMP at market outperform
|